Fitusiran in haemophilia: a breakthrough drug with many unknowns

Affiliations

¹ Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Department of Transplantation, Università degli Studi di Milano, Milan 20122, Italy. Electronic address: flora.peyvandi@unimi.it.
² Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

Comment

Flora Peyvandi et al. Lancet. 2023.

. 2023 Apr 29;401(10386):1400-1401.

doi: 10.1016/S0140-6736(23)00514-7. Epub 2023 Mar 29.

¹ Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Department of Transplantation, Università degli Studi di Milano, Milan 20122, Italy. Electronic address: flora.peyvandi@unimi.it.
² Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

No abstract available

Comment on

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, Tran H, Sun J, Wu R, Poloskey S, Qiu Z, Kichou S, Andersson S, Mei B, Rangarajan S. Young G, et al. Lancet. 2023 Apr 29;401(10386):1427-1437. doi: 10.1016/S0140-6736(23)00284-2. Epub 2023 Mar 29. Lancet. 2023. PMID: 37003287 Clinical Trial.